Results 101 to 110 of about 78,276 (237)
Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. [PDF]
Do, Thao P +7 more
core +2 more sources
Pharmacogenomic Characterization in Bipolar Spectrum Disorders [PDF]
Stefano Fortinguerra +4 more
openalex +1 more source
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai +11 more
wiley +1 more source
Background and Aims Pharmacists have been recognized as one of the most qualified healthcare professionals in the clinical implementation of pharmacogenomics, yet its widespread implementation in clinical pharmacy practice has remained limited.
Amanda Wondrasek +5 more
doaj +1 more source
Genetic polymorphisms analysis of pharmacogenomic VIP variants in Bai ethnic group from China [PDF]
Wanlu Chen +6 more
openalex +1 more source
Equal access to pharmacogenomics testing: The ethical imperative for population‐wide access in the UK NHS [PDF]
Emma Magavern, Mark J. Caulfield
openalex +1 more source
Pharmacogenetics of follicle‐stimulating hormone action in the male
Abstract Male factor infertility (MFI) is involved in half of the cases of couple infertility. The follicle‐stimulating hormone (FSH) therapy is considered efficient to improve semen parameters and pregnancy rate in patients with idiopathic MFI, following the lesson learned from hypogonadotropic hypogonadism.
Andrea Graziani +7 more
wiley +1 more source
Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response [PDF]
Ivan Jančić, Nevena Arsenović-Ranin
openalex +1 more source
Targeting hexokinase 2 to induce breast cancer cell senescence
Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof +8 more
wiley +1 more source
PharmacoDB 2.0 : Improving scalability and transparency of in vitro pharmacogenomics analysis [PDF]
Nikta Feizi +15 more
openalex +1 more source

